Jean Boulle Group created the company in 2019 to advance opportunities in nanomedicine. The company negotiated with, and acquired a license agreement from the Icahn School of Medicine at Mount Sinai and RadboudUMC. This conferred the right to develop a promising early stage technology and to establish the Company’s own IP in immunology. The Jean Boulle Group then led a significant initial funding round before establishing a scientific team including Mihai Netea, best known for his renowned research work on the innate immune system and Willem Mulder, who developed Trained Therapeutix Discovery’s proprietary nanomedicine technology platform. Mr Manfredi Lefebvre D’Ovidio, through the privately owned Heritage Group, joined the Jean Boulle Group as a founder with the aim of meaningfully exploiting a number of immunotherapeutic opportunities. These founding shareholders continue to attract new investors and expand the company’s capital base.
Company history
Board of Directors
Management
TEAM
COMPANY FOUNDERS
SCIENTIFIC FOUNDERS
Willem Mulder, PhD
Professor of Precision Medicine, Eindhoven University of Technology, The Netherlands
Department of Internal Medicine of the Radboud University Medical Center
Professor of Radiology, Icahn School of Medicine at Mount Sinai, New York
Zahi Fayad, PhD
Lucy G. Moses Professor in Medical Imaging and Bioengineering
Professor of Radiology & Medicine (Cardiology)
Director, BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York
Jordi Ochando, PhD
Assistant Professor of Medicine, Icahn School of Medicine at Mount Sinai, New York
Director, Sinai’s Flow Cytometry Core
Leo Joosten, PhD
Professor of Inflammatory Diseases, Radboud University Medical Center, The Netherlands
Head of the Laboratory of Experimental Internal Medicine, Radboud UMC
Mihai Netea, MD, PhD
Professor of Experimental Medicine, Radboud University Medical Center, The Netherlands
Partners
